Knowledge Base

Evidera had several representatives in attendance at NICE's Annual Conference to garner insight into their perspective on improving access to innovative treatments and what it means for our clients. Read More

This guide walks US-based clinical supply professionals through the EU GMP Annex 13 labeling requirements. Read More

What does the word “feasibility” mean to you? It may seem like a simple question, but I have found that “feasibility” has many interpretations within the clinical research industry. When we work with Read More

The requirement that new drugs show effectiveness is based on a 1962 amendment to the Federal Food, Drug, and Cosmetic Act. This law requires substantial evidence of effectiveness and specifies that t Read More

When it comes to the conduct of pediatric clinical trials, there are number of things you need to consider in order to ensure the successful conduct of a study. While we can’t predict the outcome, pla Read More

The term patient centricity is fraught with uncertainty for many. This term carries the nuances of widely varying practical application methods as well as theoretical disagreements from stakeholders Read More

As of May 2018, U.S. sponsors of clinical studies conducted in the EU must be in compliance with EU's new General Data Protection Regulation or risk possibility of fines. Read More